SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer. He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
SystImmune是一家處于臨床階段的前沿生物制藥公司，專(zhuān)注于開(kāi)發(fā)用于癌癥治療的新型雙特異性、多特異性抗體及抗體藥物偶聯(lián)物（ADCs）。公司今天宣布任命Jonathan Cheng博士為SystImmune新任首席醫(yī)學(xué)官。在加入SystImmune之前，Cheng博士在百時(shí)美施貴寶擔(dān)任高級(jí)副總裁兼腫瘤發(fā)展主管，負(fù)責(zé)管理抗腫瘤管線的臨床后期開(kāi)發(fā)。通過(guò)本次任命，Cheng 博士接替了Martin Olivo 博士，后者為尋求外部發(fā)展機(jī)會(huì)已離開(kāi)SystImmune。
“I am excited to welcome Dr. Cheng to our leadership team,” said Jie D’Elia, Ph.D., Chief Ｅxecutive Officer of SystImmune. “His global oncology development expertise and in-depth regulatory knowledge will accelerate our efforts to advance SystImmune’s pipeline and transform patient care. On behalf of the SystImmune team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and contributions to SystImmune. We wish him well in his future endeavors.”
SystImmune首席執(zhí)行官Jie D'Elia博士表示：“我很高興并歡迎Cheng博士加入我們的領(lǐng)導(dǎo)團(tuán)隊(duì)。他在全球腫瘤藥物開(kāi)發(fā)領(lǐng)域的專(zhuān)業(yè)沉淀和對(duì)行業(yè)監(jiān)管的深刻理解，將加速SystImmune的管線進(jìn)度，并進(jìn)一步推動(dòng)我們對(duì)患者治療的變革。我謹(jǐn)代表SystImmune團(tuán)隊(duì)，向Martin Olivo博士對(duì)公司的奉獻(xiàn)表示深深的謝意。我們祝愿他在未來(lái)一切順利?！?/span>
Dr. Yi Zhu, Chairman of SystImmune, stated “Dr. Cheng brings a wealth of expertise and a remarkable track record in oncology drug development, making him an invaluable addition to SystImmune’s Ｅxecutive leadership team.”
SystImmune董事長(zhǎng)朱義博士表示：“Cheng博士在腫瘤藥物開(kāi)發(fā)領(lǐng)域擁有豐富的專(zhuān)業(yè)知識(shí)和卓越的業(yè)績(jī)，他的加入讓SystImmune領(lǐng)導(dǎo)團(tuán)隊(duì)更加壯大。”
Dr. Cheng’s career spans both the pharmaceutical industry and academia, where he has consistently demonstrated exceptional leadership and a passion for advancing cancer treatments. Under Dr. Cheng’s leadership, BMS developed and received regulatory approval for multiple important medicines, including Nivolumab, Ipilimumab, Relatlimab, and Repotrectinib. His strategic vision also enhanced BMS’s internal and collaboration portfolio. Previously, Dr. Cheng served as Therapeutic Area Head of Oncology at Merck and led teams in securing approvals for Pembrolizumab and Lenvatinib across multiple oncology indications. Prior to his career in the pharmaceutical industry, Dr. Cheng had a successful academic career at Fox Chase Cancer Center, where he conducted groundbreaking research as the principal investigator in tumor stromal biology, resulting in over 150 original manuscripts and abstracts. Dr. Cheng received a BS from Marquette University and an MD from the University of Minnesota.
Cheng博士的職業(yè)生涯跨越制藥行業(yè)和學(xué)術(shù)界，在推動(dòng)癌癥治療方面始終展現(xiàn)了非凡的領(lǐng)導(dǎo)能力和熱情。在他的領(lǐng)導(dǎo)下，BMS開(kāi)發(fā)并上市了多種重要藥物，包括Nivolumab、Ipilimumab、Relatlimab和Repotrectinib。他的戰(zhàn)略遠(yuǎn)見(jiàn)，增強(qiáng)了該公司內(nèi)部產(chǎn)品線以及合作管線的競(jìng)爭(zhēng)力。在加入BMS之前，Cheng博士為默沙東腫瘤臨床研究副總裁，并領(lǐng)導(dǎo)團(tuán)隊(duì)取得Pembrolizumab和Lenvatinib在多個(gè)腫瘤適應(yīng)癥的上市獲批。在進(jìn)入制藥行業(yè)之前，Cheng博士在 Fox Chase 癌癥中心擁有成功的學(xué)術(shù)生涯。他作為腫瘤基質(zhì)生物學(xué)的首席研究員，進(jìn)行了開(kāi)創(chuàng)性的研究，并形成150 多份原始手稿和摘要。Cheng博士獲得馬凱特大學(xué)學(xué)士學(xué)位和明尼蘇達(dá)大學(xué)醫(yī)學(xué)博士學(xué)位。
For further information, please contact: info@systimmune.com
如需更多信息，請(qǐng)聯(lián)系:info@systimmune.com
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.
關(guān)于SystImmune
SystImmune是一家位于華盛頓州雷德蒙德的處于臨床階段的生物制藥公司。該公司專(zhuān)注于利用其成熟的藥物開(kāi)發(fā)平臺(tái)，開(kāi)發(fā)創(chuàng)新的癌癥治療方法，包括雙特異性、多特異性抗體及抗體藥物偶聯(lián)物（ADCs）。SystImmune在實(shí)體瘤和血液病領(lǐng)域的多個(gè)臨床試驗(yàn)階段均擁有管線和技術(shù)儲(chǔ)備。除了正在進(jìn)行的臨床試驗(yàn)外，公司還擁有強(qiáng)大的臨床前管線，包括處于發(fā)現(xiàn)階段或IND階段的潛在癌癥治療藥物，代表著公司在生物制藥開(kāi)發(fā)領(lǐng)域的領(lǐng)先實(shí)力。
